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Background: Characterising the correlates of HIV persistence improves understanding of disease pathogenesis
and guides the design of curative strategies. This study investigated factors associated with integrated HIV-1
DNA load during consistently suppressive ﬁrst-line antiretroviral therapy (ART).
Method: Total, integrated, and 2-long terminal repeats (LTR) circular HIV-1 DNA, residual plasma HIV-1 RNA,
T-cell activation markers, and soluble CD14 (sCD14) were measured in peripheral blood of 50 patients that
had received 1–14 years of efavirenz-based or nevirapine-based therapy.
Results: Integrated HIV-1 DNA load (per 106 peripheral blood mononuclear cells) was median 1.9 log10 copies
(interquartile range 1.7–2.2) and showed a mean difference of 0.2 log10 copies per 10 years of suppressive ART
(95% conﬁdence interval−0.2, 0.6; p = 0.28). It was positively correlated with total HIV-1 DNA load and fre-
quency of CD8+HLA-DR/DP/DQ+ cells, and was also higher in subjects with higher sCD14 levels, but showed
no correlation with levels of 2-LTR circular HIV-1 DNA and residual plasma HIV-1 RNA, or the frequency of
CD4+CD38+ and CD8+CD38+ cells. Adjusting for pre-ART viral load, duration of suppressive ART, CD4 cell
counts, residual plasmaHIV-1RNA levels, and sCD14 levels, integratedHIV-1DNA loadwasmean 0.5 log10 copies
higher for each 50% higher frequency of CD8+HLA-DR/DP/DQ+ cells (95% conﬁdence interval 0.2, 0.9; p= 0.01).
Conclusions: The observed positive association between integrated HIV-1 DNA load and frequency of CD8+DR/
DP/DQ+ cells indicates that a close correlation betweenHIV persistence and immune activation continues during
consistently suppressive therapy. The inducers of the distinct activation proﬁle warrant further investigation.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).us type 1; HIV-1 VL, HIV-1 viral load; ART, Anti-retroviral therapy; HIC, HIV-1 controllers; NNRTI, Non-nucleoside reverse-
se transcriptase inhibitors; VLS, Viral Load Suppression; PBMCs, Peripheral blood mononuclear cells; 2-LTR, 2-long terminal re-
gen; CMV, cytomegalovirus virus; EBV, Epstein-Bar virus; NIHR, National Institute for Health Research; CRN, Clinical Research
e-linked immune-enzymatic assay; PFA, paraformaldehyde; LPS, lipopolysaccharide; PCR, Polymerase chain reaction.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Early after transmission, HIV establishes a reservoir of replication-
competent integrated provirus that resides predominantly within
memory CD4 T cells, is unresponsive to antiretroviral therapy (ART),
and rapidly fuels resumption of virus replication upon treatment dis-
continuation (Ruelas and Greene, 2013; Soriano-Sarabia et al., 2014;
Siliciano et al., 2003). The mechanisms underlying HIV persistence
have not been fully elucidated and proposed models are not mutually
exclusive. Continuous replenishment of the reservoir may occur
through ongoing virus production (Hatano et al., 2013; Buzon et al.,
2010), perhaps in sites where ART penetration or activity is suboptimal
(Fletcher et al., 2014). In the absence of virus production, maintenance
of the reservoir can also occur through proliferation of latently infected
CD4T-cells, as a possibly key determinant of HIV persistence duringART
(Maldarelli et al., 2014; Josefsson et al., 2013; Chomont et al., 2009;
Wagner et al., 2014).
HIV replication causes chronic immuneactivation and inﬂammation,
typically accompanied by an expansion of CD8 T-cells, which improve
but rarely resolve with ART (Klatt et al., 2013). Persistent HIV produc-
tion or partial antigenic expression may drive ongoing immune activa-
tion in treated patients. In turn, immune activation can promote T-cell
proliferation, HIV transcription, and virus production (Klatt et al.,
2013). Furthermore, early in the course of the infection, HIV-induced
gut damage allows translocation of gastrointestinal microbial products
into the systemic circulation, and the resulting immune activation
causes further gut damage, establishing a self-perpetuating cycle that
can become independent of virus production (Shan and Siliciano,
2014). Other persistent infections, for example with cytomegalovirus
(CMV), have also been linked with ongoing immune activation despite
suppressive ART (Gianella et al., 2014).
There are inconsistent data on how markers of immune activation
correlatewith parameters of HIV persistence during long-term suppres-
sive therapy, possibly a consequence of heterogeneous study popula-
tions and measures of HIV persistence, but also a reﬂection of complex
bilateral interactions (Hatano et al., 2013; Chun et al., 2011;
Cockerham et al., 2014). There remains a need to characterise this rela-
tionship further in order to improve our understanding of HIV patho-
genesis and design improved curative strategies. The aim of this study
was to investigate factors associated with the levels of integrated HIV-
1 DNAmeasured in peripheral blood during stably suppressive ART, in-
cluding the relationship with markers of immune activation. Efforts
were taken to minimise heterogeneity of the study population, by
exclusively selecting patients who started ﬁrst-line ART with two
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus
one non-nucleoside reverse transcriptase inhibitor (NNRTI), achieved a
plasma HIV-1 RNA (“viral”) load b50 copies/ml within six months of
starting ART, and subsequently showed consistent viral load suppression
b50 copies/ml over up to 14 years of continuous treatment on the same
NNRTI.
2. Methods
2.1. Study population
Study subjects were recruited at clinical centres across the United
Kingdom (see study group). Eligible patients had started ﬁrst-line ART
with two NRTIs plus efavirenz or nevirapine, achieved viral load sup-
pression b50 copies/ml within six months of starting therapy, and sub-
sequently showed all viral load measurements b50 copies/ml whilst
undergoing ≥2 viral load measurements per year, without transient
elevations above 50 copies/ml or treatment interruptions. Changes of
the initial NNRTI were not allowed. Changes of the initial NRTI (e.g., for
toxicity) were allowed provided they were not associated with a treat-
ment interruption or viral load rebound N50 copies/ml. Recruitment
was stratiﬁed by duration of ART to range from 1 to over 10 years. Thestudy was approved by National Research Ethics Service (London-
Dulwich) and was included in the National Institute for Health Research
Clinical Research Network (NIHR CRN) Portfolio. All patients provided
written informed consent.
2.2. Quantiﬁcation of residual HIV-1 RNA in plasma
Plasma HIV-1 RNA below 50 copies/ml was quantiﬁed using a mod-
iﬁed version of the Abbott RealTimeHIV-1 assay (Maidenhead, UK), fol-
lowing ultracentrifugation of 8 ml of plasma at 215,000 g for 45′ at 4 °C,
and resuspension of the pellet in 1 ml of basematrix (SeraCare, USA).
Each run included negative, low positive, and high positive controls.
Assay sensitivity was determined by spiking HIV-negative plasma
with four dilutions of the World Health Organisation (WHO) 3rd Inter-
national Standard for HIV-1 RNA in triplicate (NIBSC code:10/152,
Hertfordshire, UK). The assay 50% and 95% detection rates for 8 ml
input were 1 and 3 HIV-1 RNA copies/ml, respectively.
2.3. HIV-1 subtyping
TheHIV-1 subtypewas determined using polymerase sequences ob-
tained from HIV-1 DNA recovered from PBMC, as previously described
(Geretti et al., 2014).
2.4. Quantiﬁcation of total, integrated and 2-LTR circular HIV-1 DNA in
peripheral blood mononuclear cells
Total HIV-1 DNA load in peripheral bloodmononuclear cells (PBMC)
was determined by a quantitative real-time PCR targeting a conserved
LTR region as previously described (Geretti et al., 2013). The assay 50%
and 95% detection rates were 20 and 40 HIV-1 DNA copies/106 PBMC,
respectively. Integrated HIV-1 DNA was quantiﬁed by repetitive-
sampling Alu-PCR as previously described (De Spiegelaere et al., 2014)
using the primers shown in Supplementary Table 1. Brieﬂy, 42 replicate
Alu-HIV-1 PCR ampliﬁcations were performed with gag reverse HIV-1
primer and Alu forward primer for integrated HIV-1 DNA, and 32 repli-
cates with only HIV-1 gag primers for unintegrated HIV-1 DNA. After
ampliﬁcation, the ﬁrst PCR product was subjected to a nested quantita-
tive PCR targeting the HIV-1 LTR RU5 region. The integrated HIV-1 DNA
copy numberwas calculated according to Poisson's principleswith error
estimation including theWilsonmethod (www.integratedhivpcr.ugent.
be). Four Alu-HIV positive wells were required as output to allow
reliable quantiﬁcation. 2-LTR circular HIV-1 DNA levels were measured
by droplet digital PCR as previously described (Strain et al., 2013); the
lower limit of detection was median 5 copies/106 PBMC (interquartile
range, IQR 4–6).
2.5. Markers of immune activation
Cellular markers were measured by staining freshly isolated PBMC
with PE or FITC labelled antibodies against CD4 plus either CD26,
CD38, or CD69, and against CD8 plus either CD38 or HLA-DR/DP/DQ
(Serotec, Oxford, UK; Becton Dickinson, NJ, USA). Cell suspensions
were ﬁxed with 1% paraformaldehyde (PFA) prior to acquisition using
FACScan and analysis byCellQuest software version3.3 (BectonDickinson
NJ, USA). Soluble CD14 (sCD14) as a marker of bacterial lipopolysaccha-
ride (LPS)-induced monocyte/macrophage activation was measured in
plasma by enzyme-linked immune-enzymatic assay (ELISA) (R&D Sys-
tem sCD14 ELISA, Abington, UK).
2.6. Detection of cytomegalovirus and Epstein–Barr virus DNA
Plasma was tested for CMV and Epstein–Barr Virus (EBV) DNA with
a real-time PCR assay targeting the viral UL123/UL55 and p143 regions,
respectively. The lower limits of detection were 50 IU/ml for CMV DNA
and 100 copies/ml for EBV DNA.
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Duration of suppressive ART was deﬁned as the length of time fol-
lowing the ﬁrst viral load measurement b50 copies/ml recorded after
starting ART. The characteristics of the study population stratiﬁed into
two groups based upon duration of suppressive ART, integrated HIV-1
DNA load, or frequency of CD8+HLA-DR/DP/DQ+ cells were compared
using non-parametricWilcoxon andMann–Witney tests for continuous
variables, and the Fisher's exact test for categorical variables. Where the
analyses required variables to be expressed in median levels, undetect-
able HIV-1 RNA resultswere given an arbitrarymidpoint value between
zero and the assay 95% detection rate (=1.5 copies/ml), whereas unde-
tectable 2-LTR circular HIV-1 DNA results were assigned a midpoint
value between zero and the assay median lower limit of detection
(=2.5 copies/106 PBMC). Mean differences (with 95% conﬁdence inter-
val, CI) in measured residual plasma HIV-1 RNA, 2-LTR circular HIV-1
DNA, total and integratedHIV-1 DNA, sCD14, and frequency of activated
CD4 and CD8 cells over 10 years of suppressive ART were analysed by
univariate linear regression analysis after log transformation of the var-
iables. The correlation between integrated HIV-1 DNA load or frequency
of CD8+HLA-DR/DP/DQ+ cells and other measured parameters was ex-
plored by the Spearman's test. The association between integrated HIV-
1 DNA load and other variables was characterised further by univariate
and multivariable linear regression modelling. A ‘best subset’ approach
and theMallow Cp test were used for the selection of variables to be in-
cluded in the multivariable model. All available variables were initially
considered for inclusion, with the exception of gender and NNRTI use
(due to predominance of males and efavirenz use: 40/50, 80% for both
variables) and total HIV-1 DNA load (due to strong co-linearity with in-
tegrated HIV-1 DNA load). Pre-ART viral load (Cp value 3.5), duration of
suppressive ART (3.6), residual plasmaHIV-1 RNA load (3.6), frequency of
CD8+HLA-DR/DP/DQ+ cells (0.4), and sCD14 levels (1.7) were identiﬁed
for inclusion in the multivariate model. The CD4 cell count was added to
the multivariable model as a possible confounding factor. In a second
multivariable model, nadir CD4 count was included instead of pre-ART
viral load. A sensitivity analysis was also performed replacing integratedTable 1
Characteristics of the study population overall and stratiﬁed by duration of suppressive therap
Characteristic Total (n = 50)
Male n (%) 40 (80)
Age median years (IQR) 46 (40–53)
HIV-1 subtype B n (%) 32 (64)
Nadir CD4 count median cells/mm3 (IQR) 206 (110–265)
Duration of ART median years (IQR) 6.7 (3.4–9.1)
Duration of suppressive ART median years (IQR)a 6.4 (3.1–8.8)
Efavirenz as initial NNRTI n (%) 40 (80)
Changed NRTI backbone n (%) 25 (50)
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 5.0 (4.7–5.5)
Detectable residual plasma HIV-1 RNA n (%) 29 (58)
Residual HIV-1 RNA median copies/ml (IQR)b 2 (2–4)
Detectable 2-LTR circular HIV-1 DNA n (%) 16 (32)
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR)c 3 (3–7)
Total HIV-1 DNA median log10 copies/106 PBMC (IQR) 2.6 (2.3–2.9)
Integrated HIV-1 DNA median log10 copies/106 PBMC (IQR) 1.9 (1.7–2.2)
CD4 count median cells/mm3 (IQR) 572 (478–734)
CD4+CD26+ median percentage (IQR) 54 (43–63)
CD4+ CD38+ median percentage (IQR) 22 (17–34)
CD4+CD69+ median percentage (IQR) 2 (1–2)
CD8+CD38+ median percentage (IQR) 5 (3–7)
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 32 (20–48)
sCD14 median μg/ml (IQR) 2.2 (1.8–2.6)
IQR= interquartile range; ART= antiretroviral therapy; NRTI= nucleoside/nucleotide reverse
peripheral blood mononuclear cells; sCD14 = soluble CD14.
a Deﬁned as the length of time following the ﬁrst viral load b50 copies/ml; it ranged betwee
b Samples with undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/ml.
c Samples with undetectable 2-LTR circular HIV-1 DNA were assigned an arbitrary value of 2with total HIV-1 DNA as the outcome variable in the same two models.
The analyses were performed with SAS 9.4.
3. Results
3.1. Study population
The cohort comprised 50 patients who at the time of sampling were
receiving two NRTIs plus either efavirenz (80%) or nevirapine and had a
median duration of viral load suppression b50 copies/ml of 6.4 years
(Table 1). Patients with duration of suppressive ART above the median
of 6.4 years were older and had a lower nadir CD4 cell count, a margin-
ally higher current CD4 cell count, and lower frequencies of CD4 and
CD8 cells expressing CD38 relative to subjects with shorter duration.
They were also more likely to have experienced changes in the compo-
sition of the NRTI backbone after ﬁrst starting ART. Overall 25/50 pa-
tients (50%) changed one or more component of the NRTI backbone,
with median 1 drug change per subject (IQR 0–1). At the time of sam-
pling, NRTI backbones were tenofovir/emtricitabine (37/50, 74%),
abacavir/lamivudine (10/50, 20%), or zidovudine/lamivudine (3/50,
6%). Residual plasma HIV-1 RNA was detected in 29/50 patients (58%)
at levels ranging between 1 and 35 copies/ml, whereas 2-LTR circular
HIV-1 DNA was detected in 16/50 patients (32%) at levels ranging be-
tween 5 and 35 copies/106 PBMC. All subjects had detectable HIV-1
DNA, with total and integrated HIV-1 DNA levels of median 2.6 and
1.9 log10 copies/106 PBMC, respectively. None of the patients had de-
tectable CMVDNA in plasma,whereas 3/50patients (6%)had detectable
EBV DNA.
Differences inmeasured parameters per 10 years of suppressive ART
were determined by linear regression analysis of data obtained from the
cross-sectional sampling (Table 2). Longer duration of suppressive ART
was associated with higher CD4 cell counts and lower levels of CD38
expression on CD4 and CD8 cells. There were also lower 2-LTR circular
HIV-1 DNA levels and a trend for lower residual HIV-1 RNA levels. A
sub-analysis compared subjects with integrated HIV-1 DNA load either
in the lowest quartile (b1.7 log10 copies/106 PBMC) or the highesty as below (Group I) or above (Group II) the median of 6.4 years.
Group I (n = 25) Group II (n = 25) P
22 (88) 18 (72) 0.29
44 (36–49) 48 (43–55) 0.04
18 (72) 14 (56) 0.38
246 (160–292) 176 (97–213) 0.007
3.4 (2.5–5.0) 9.2 (8.0–10.3) b0.001
3.1 (2.1–4.8) 9.0 (7.7–10.0) b0.001
22 (44) 18 (36) 0.29
4 (16) 21 (84) b0.001
4.8 (4.5–5.3) 5.1 (4.9–5.6) 0.09
15 (60) 14 (56) 1.00
2 (2–7) 2 (2–4) 0.33
10 (40) 6 (25) 0.36
3 (3–7) 3 (3–5) 0.28
2.6 (2.4–2.9) 2.5 (2.2–2.7) 0.36
1.9 (1.7–2.1) 1.8 (1.7–2.4) 0.91
552 (442–606) 640 (502–794) 0.05
54 (42–63) 54 (44–63) 0.55
25 (21–35) 20 (14–24) 0.02
1 (1–3) 2 (1–2) 0.48
6 (3–8) 4 (3–6) 0.04
37 (22–53) 30 (16–42) 0.19
2.0 (1.6–2.6) 2.2 (2.0–2.7) 0.16
transcriptase inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; PBMC=
n 0.7 and 6.4 years in Group 1, and between 6.4 and 14.4 years in Group II.
.5 copies/106 PBMC.
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quartile showed signiﬁcant lower levels of total HIV-1 DNA and sCD14,
and lower frequency of CD8+HLA-DR/DP/DQ+ cells.
3.2. Factors associated with integrated HIV-1 DNA load
Integrated HIV-1 DNA load was positively correlated with total HIV-
1 DNA load (p b 0.0001), frequency of CD8+HLA-DR/DP/DQ+ cells (p=
0.01), and sCD14 levels (p = 0.04), but not with the levels of residual
plasma HIV-1 RNA (p = 0.81) and 2-LTR circular HIV-1 DNA (p =
0.50), or the frequency of CD8+CD38+ cells (p = 0.33) (Fig. 1). The as-
sociations were also tested by univariate and multivariable linear re-
gression analysis (Table 4). A ﬁrst model was built including pre-ART
viral load, duration of suppressive ART, CD4 cell counts, residual plasma
HIV-1 RNA levels, frequency of CD8+HLA-DR/DP/DQ+ cells, and sCD14
levels. In this adjustedmodel, integrated HIV-1 DNA loadwas amean of
0.5 log10 copies higher for each 50% increment in the frequency of
CD8+HLA-DR/DP/DQ+ cells (95% CI 0.2, 0.9; p = 0.01) (Table 4).
The association between integrated HIV-1 DNA load and frequency
of CD8+HLA-DR/DP/DQ+ cells was conﬁrmed in a separate model in-
cluding the nadir CD4 cell count in place of pre-ART viral load. In this
second model integrated HIV-1 DNA load was mean 0.5 log10 copies
higher for each 50% increase in the frequency of CD8+HLA-DR/DP/
DQ+ cells (95% CI 0.1, 0.8; p= 0.02) (Supplementary Table 2). In a sen-
sitivity analysis, integrated HIV-1 DNA was replaced with total HIV-1
DNA in the two multivariable models (Supplementary Table 3). In the
model including pre-ART viral load as one of variables, total HIV-1
DNA load was 0.4 log10 copies higher for each 50% increase in the fre-
quency of CD8+HLA-DR/DP/DQ+ cells (95% CI−0.02, 0.8; p = 0.06);
in the model including the nadir CD4 cell count in place of pre-ART
viral load, total HIV-1 DNA load was similarly 0.5 log10 copies higher
for each 50% increase in the frequency of CD8+HLA-DR/DP/DQ+ cells
(95% CI−0.1, 0.8; p=0.12).We found no evidence that the association
between integrated HIV-1 DNA load and frequency of CD8+HLA-DR/
DP/DQ+ cells varied by HIV-1 subtype (B vs. non-B) (not shown).
4. Discussion
This analysis of subjects receiving ﬁrst-line NNRTI-based ART dem-
onstrated that integrated HIV-1 DNA load did not differ by duration of
suppressive therapy and was positively associated with the frequency
of CD8 cells expressing HLA-DR/DP/DQ. Subjects with higher integrated
HIV-1 DNA load also had higher levels of sCD14, although the associa-
tion did not persist in adjusted analyses. Whilst there was a predictable
positive correlation with total HIV-1 DNA levels, integrated HIV-1 DNA
load did not show a correlation with putative measures of recent HIV-
1 replication (residual plasma HIV-1 RNA, 2-LTR circular HIV-1 DNA),
or with the frequency of CD4 and CD8 cells expressing CD38.Table 2
Univariate linear regression analysis ofmean difference in log-transformed virological and
immunological variables per 10 years of suppressive antiretroviral therapy.
Variablea Mean difference 95% CI P
Residual HIV-1 RNA copies/ml −0.27 −0.57, 0.03 0.08
2-LTR circular HIV-1 DNA copies/106 PBMC −0.34 −0.59,−0.08 0.01
Total HIV-1 DNA copies/106 PBMC −0.12 −0.56, 0.32 0.60
Integrated HIV-1 DNA copies/106 PBMC 0.22 −0.19, 0.62 0.28
CD4 count cells/mm3 0.14 0.00, 0.27 0.05
CD4+CD26+ percentage −0.03 −0.02, 0.10 0.69
CD4+CD38+ percentage −0.23 −0.39,−0.07 0.01
CD4+CD69+ percentage −0.11 −0.28, 0.07 0.22
CD8+CD38+ percentage −0.30 −0.54,−0.07 0.01
CD8+HLA-DR/DP/DQ+ percentage −0.15 −0.37, 0.07 0.17
sCD14 μg/ml 0.07 −0.03, 0.16 0.19
CI = Conﬁdence interval; PBMC= peripheral blood mononuclear cells; sCD14= soluble
CD14.
a Variables in log10.Previous studies reported that during suppressive ART integrated
HIV-1 DNA shows a constant load and little evidence of genetic evolu-
tion (Siliciano et al., 2003; Josefsson et al., 2013; von Stockenstrom
et al., 2015; Besson et al., 2014). Our study adds to these previous anal-
yses by demonstrating that HIV-1 DNA load did not differ by duration of
suppressive therapy in a population with a relatively homogenous
treatment history and exact requirements in terms of evidence of plas-
ma viral load suppression b50 copies/ml. There were indications that
subjects treated for longer had lower levels of 2-LTR circular HIV-1
DNA and residual plasma HIV-1 RNA, accompanied by a reduction in
the frequency of CD4+CD38+ and CD8+CD38+ cells, together suggest-
ing that control of virus replication and resolution of immune dysfunc-
tion improvewith longer duration of therapy. In contrast, the frequency
of CD8+HLA-DR/DP/DQ+ cells was also not related to the duration of
suppressive ART and we were able to quantify the association between
two key parameters of virus persistence and immune activation,where-
by integrated HIV-1 DNA load increased by 0.5 log10 copies/106 PBMC
for each 50% increase in the frequency of CD8+HLA-DR/DP/DQ+ cells.
The function of CD8+ cells expressing HLA-DR/DP/DQ+ remains to
be fully elucidated and may include both regulatory and effector func-
tions (Arruvito et al., 2014; Saez-Cirion et al., 2007; Zubkova et al.,
2014). In the context of suppressive ART, CD8+CD38−/HLA-DR+ cells
may be maintained by low-level expression of HIV or, other persistent
pathogens, including microbial translocation from the gut. It has been
proposed that CD8+ cells expressing HLA-DR without CD38 are prefer-
entially generated in response to low antigenic stimulation and that by
retaining good effector function,may play a role in suppressingHIV rep-
lication in elite controllers, as well as clearing hepatitis C infection
(Saez-Cirion et al., 2007; Zubkova et al., 2014). It may seem therefore
counterintuitive that CD8+HLA-DR/DP/DQ+ cells should have a positive
(rather than inverse) correlation with integrated HIV-1 DNA load. Yet,
in line with previous data (Hatano et al., 2013), our adjusted analyses
showed a positive association between frequency of CD8+38-HLA-DR/
DP/DQ+ cells and integrated HIV-1 DNA load. Several hypotheses may
be proposed to explain the observed positive association. Firstly,
low-level HIV production may both stimulate CD8+HLA-DR/DP/DQ+
cells and continuously replenish the integrated reservoir. Further,
CD8+HLA-DR/DP/DQ+ cells may directly stimulate HIV-infected CD4
cells, causing their proliferation and expansion of the reservoir, which
can be measured as increased integrated HIV-1 DNA load (Klatt et al.,
2013). Thirdly, a stimulant or multiple stimulants may act simulta-
neously on CD8+HLA-DR/DP/DQ+ cells and HIV-infected CD4 cells,
resulting in an indirect association between the two parameters.
The populationwe studied did not overall show evidence of ongoing
HIV replication. Patients experienced no viral load rebound N50 copies/
ml during follow-up (Doyle et al., 2012). In line with previous studies,
just over half had traces of detectable plasma HIV-1 RNA (Palmer
et al., 2008), whereas a third had detectable intracellular 2-LTR circular
HIV-1 DNA. Therewas no association however between these two puta-
tive markers of recent HIV-1 replication and either integrated HIV-1
DNA load, or the frequency of CD8+HLA-DR/DP/DQ+ cells (data not
shown). Whilst this indicates that HIV production was unlikely, the
ﬁnding may also reﬂect insufﬁcient sensitivity of the analytic systems
and the limitation of assaying peripheral blood (Cockerham et al.,
2014). It will be important to determine the antigenic speciﬁcity of
CD8+HLA-DR/DP/DQ+ cells, for example against persistent viruses
such as CMV and EBV (Gianella et al., 2014). The two herpes viruses
were not commonly detected in our population, which is consistent
with containment by effective immune responses. One other aspect
that warrants investigation is the relationship with levels of sCD14,
which are an important predictor of disease progression and mortality
in both treated and untreated patients (Sandler et al., 2011; Marchetti
et al., 2011; Hunt et al., 2014). In this study, median sCD14 levels were
within the range reported in healthy HIV-negative controls (Sandler
et al., 2011). However, patients whose integrated HIV-1 DNA load fell
within the highest quartile showed signiﬁcantly higher sCD14 levels
Table 3
Comparative analysis of subjects whose integrated HIV-1 DNA load fell within the lowest or the highest quartilesa.
Characteristic Lowest quartile (n = 13) Highest quartile (n = 13) P
Integrated HIV-1 DNA median log10 copies/106 PBMC (IQR) 1.4 (1.4–1.6) 2.6 (2.5–2.9) b0.0001
Male n (%) 9 (70) 11 (84) 0.64
Age median years (IQR) 40 (31–49) 47 (43–53) 0.07
HIV-1 subtype B n (%) 8 (61) 5 (38) 0.43
Nadir CD4 count median cells/mm3 (IQR) 180 (80–240) 208 (118–260) 0.41
Duration of ART median years (IQR) 6.7 (5.7–8.2) 9.1 (3.0–10.7) 0.29
Duration of suppressive ART median years (IQR) 6.6 (5.7–7.7) 8.9 (2.7–10.6) 0.24
Efavirenz as initial NNRTI n (%) 13 (100) 10 (77) 0.22
Changed NRTI backbone n (%) 8 (61) 5 (38) 0.43
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 4.9 (4.6–5.5) 5.1 (5.0–5.5) 0.26
Detectable residual plasma HIV-1 RNA n (%) 9 (69) 6 (46) 0.43
Residual HIV-1 RNA median copies/ml (IQR) 2 (2–3) 2 (2–5) 0.89
Detectable 2-LTR circular HIV-1 DNA n (%) 4 (31) 6 (46) 0.68
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR) 3 (3–7) 3 (3–7) 0.65
Total HIV-1 DNA median log10 copies/106 PBMC (IQR) 2.4 (2.1–2.6) 2.8 (2.7–3.0) 0.003
CD4 count median cells/mm3 (IQR) 721 (552–758) 513 (482–640) 0.25
CD4+CD26+ median percentage (IQR) 53 (34–60) 54 (44–59) 0.85
CD4+ CD38+ median percentage (IQR) 23 (17–34) 20 (16–24) 0.28
CD4+CD69+ median percentage (IQR) 2 (1–2) 2 (1–2) 0.64
CD8+CD38+ median percentage (IQR) 4 (3–7) 3 (2–7) 0.43
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 24 (16–37) 35 (32–49) 0.01
sCD14 median μg/ml (IQR) 1.8 (1.6–2.3) 2.4 (2.1–2.7) 0.04
PBMC= peripheral blood mononuclear cells; IQR = interquartile range; ART = antiretroviral therapy; NNRTI = non-nucleoside reverse transcriptase inhibitor; sCD14 = soluble CD14.
a Quartile cut-offs = 1.7 and 2.2 log10 copies/106 PBMC.
1157A. Ruggiero et al. / EBioMedicine 2 (2015) 1153–1159than those with integrated HIV-1 DNA load in the lowest quartile, a
ﬁnding that warrants further investigation in larger cohorts.
A strong positive association was measured between total and inte-
grated HIV-1 DNA, supporting the notion that integrated HIV-1 DNA is
the most prevalent form of HIV-1 DNA during suppressive ART (Graf
and O'Doherty, 2013), and total HIV-1 DNAwas associatedwith the fre-
quency of CD8+HLA-DR/DP/DQ+ cells. Two previous studies have re-
ported an association between the frequency of CD8 cells expressing
HLA-DR and total HIV-1 DNA load in peripheral blood (Hatano et al.,
2013; Cockerham et al., 2014). One study was unable to detect a consis-
tent association between the expression of activation markers on CD8
cells and integrated HIV-1 DNA load among 19 subjects (Cockerham
et al., 2014). The reasons for the discrepant ﬁndings are unclear, and
may include a smaller and more heterogeneous study population rela-
tive to this cohort, as well as possible differences in the methods to
quantify integrated HIV-1 DNA load.Fig. 1.Correlation between integratedHIV-1 DNA load and a) total HIV-1DNA load, b) residual p
DP/DQ+ cells, e) frequency of CD8+CD38+ cells, and f) levels of sCD14. Scatter plots with pred
and Spearman's rho (with p values) are shown.This study has limitations. Parameters were measured cross-
sectionally, albeit after stratifying recruitment according to duration
of ART, and causality of the observed associations cannot be con-
cluded. Study size limited the number of variables included in the
multivariable analysis of factors associated with integrated HIV-1
DNA load, and unmeasured variables may have contributed to the
ﬁndings. Importantly, the cohort had received NNRTI-based ART exclu-
sively, and ﬁndings may not necessarily be extrapolated to other
treatment regimens. Further, we measured CD38 and HLA-DR/DP/DQ
expression on CD8 cells separately. Unlike the frequency of CD8+HLA-
DR/DP/DQ+ cells however, the frequency of CD8+CD38+ cells declined
with duration of suppressive ART and showed no statistical association
with integrated HIV-1 DNA load. Further analyses are needed to conﬁrm
the association between integrated HIV-1 DNA load and CD8+CD38−
HLA-DR/DP/DQ+ cells, characterise the antigenic speciﬁcity of
CD8+HLA-DR/DP/DQ+ cells, and determine the direction of causality.lasmaHIV-1 RNA levels, c) 2-LTR circular HIV-1DNA levels, d) frequency of CD8+HLA-DR/
icted HIV-1 DNA by the ﬁtted fractional polynomial curves (with 95% conﬁdence interval)
Table 4
Univariate and multivariable linear regression analysis of factors associated with the mean difference in integrated HIV-1 DNA loada.
Univariate Multivariable
Factor Mean difference 95% CI P Mean difference 95% CI P
Age, per 10 years higher 0.11 −0.03, 0.25 0.11
HIV-1 subtype B vs. non B 0.11 −0.18, 0.39 0.46
Nadir CD4 count per 100 cell/mm3 higher 0.06 −0.04, 0.17 0.25
Duration of suppressive ART per 10 years longer 0.22 −0.19, 0.62 0.28 0.23 −0.20, 0.66 0.30
Changed NRTI backbone yes vs. no −0.14 −0.41, 0.13 0.30
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.10 −0.08, 0.28 0.27 0.13 −0.05, 0.30 0.15
Residual HIV-1 RNA per log10 copies/ml higher 0.20 −0.17, 0.57 0.28 0.27 −0.08, 0.62 0.13
2-LTR circular HIV-1 DNA per log10 copies/106 PBMC higher 0.04 −0.39, 0.46 0.85
CD4 count per 100 cells/mm3 higher 0.03 −0.02, 0.08 0.25 0.02 −0.03, 0.07 0.38
CD4+CD26+ per 50% higher 0.01 −0.44, 0.47 0.96
CD4+CD38+ per 50% higher −0.78 −2.11, 0.54 0.24
CD4+CD69+ per 50% higher 1.02 −5.29, 7.33 0.75
CD8+CD38+ per 50% higher −0.27 −1.22, 0.67 0.57
CD8+HLA-DR/DP/DQ+ per 50% higher 0.38 0.02, 0.74 0.04 0.51 0.15, 0.86 0.01
sCD14 per log10 μg/ml higher 0.97 −0.14, 2.08 0.09 0.90 −0.16, 1.97 0.10
PBMC = peripheral blood mononuclear cells; ART = antiretroviral therapy; NRTI = nucleoside/nucleotide reverse transcriptase inhibitor; sCD14 = soluble CD14.
a Mean difference in log10 copies/106 PBMC.
1158 A. Ruggiero et al. / EBioMedicine 2 (2015) 1153–1159Moreover, the data describe CD8 cells expressing HLA-DR/DP/DQ and it
will be of interest to study the association between integrated HIV-1
DNA load and individual HLA isotypes. Meanwhile, our data add to
growing evidence indicating that a complex interplay between HIV-1
persistence and immune activation continues over many years of stably
suppressive ART.
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